|Liver-related deaths in persons infected with the human immunodeficiency virus: the D: A: D study|
Data Collection on Adverse Events of Anti-HIV Drugs Study Group
Archives of internal medicine 166 (15), 1632-1641, 2006
|Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D: A: D study: a multi-cohort collaboration|
D: A: D Study Group
The Lancet 371 (9622), 1417-1426, 2008
|Survival of HIV-positive patients starting antiretroviral therapy between 1996 and 2013: a collaborative analysis of cohort studies|
A Trickey, MT May, JJ Vehreschild, N Obel, MJ Gill, HM Crane, ...
The lancet HIV 4 (8), e349-e356, 2017
|Cognitive dysfunction in HIV patients despite long-standing suppression of viremia|
S Simioni, M Cavassini, JM Annoni, AR Abraham, I Bourquin, V Schiffer, ...
Aids 24 (9), 1243-1250, 2010
|Morbidity and aging in HIV-infected persons: the Swiss HIV cohort study|
B Hasse, B Ledergerber, H Furrer, M Battegay, B Hirschel, M Cavassini, ...
Clinical Infectious Diseases 53 (11), 1130-1139, 2011
|Major clinical outcomes in antiretroviral therapy (ART)–naive participants and in those not receiving ART at baseline in the SMART study|
Strategies for Management of Antiretroviral Therapy (SMART) Study Group
The Journal of infectious diseases 197 (8), 1133-1144, 2008
|Dominant TNF-α+ Mycobacterium tuberculosis–specific CD4+ T cell responses discriminate between latent infection and active disease|
A Harari, V Rozot, FB Enders, M Perreau, JM Stalder, LP Nicod, ...
Nature medicine 17 (3), 372-376, 2011
|Decreasing mortality and changing patterns of causes of death in the S wiss HIV C ohort S tudy|
R Weber, M Ruppik, M Rickenbach, A Spörri, H Furrer, M Battegay, ...
HIV medicine 14 (4), 195-207, 2013
|Characteristics, Determinants, and clinical relevance of CD4 T cell recovery to< 500 cells/µL in HIV type 1—infected individuals receiving potent antiretroviral therapy|
GR Kaufmann, H Furrer, B Ledergerber, L Perrin, M Opravil, P Vernazza, ...
Clinical infectious diseases 41 (3), 361-372, 2005
|PD-1+ and follicular helper T cells are responsible for persistent HIV-1 transcription in treated aviremic individuals|
R Banga, FA Procopio, A Noto, G Pollakis, M Cavassini, K Ohmiti, ...
Nature medicine 22 (7), 754-761, 2016
|Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: a randomised, active …|
A Mills, JR Arribas, J Andrade-Villanueva, G DiPerri, J Van Lunzen, ...
The Lancet Infectious Diseases 16 (1), 43-52, 2016
|Changing patterns of cancer incidence in the early-and late-HAART periods: the Swiss HIV Cohort Study|
S Franceschi, M Lise, GM Clifford, M Rickenbach, F Levi, M Maspoli, ...
British journal of cancer 103 (3), 416-422, 2010
|Factors associated with the incidence of type 2 diabetes mellitus in HIV-infected participants in the Swiss HIV Cohort Study|
B Ledergerber, H Furrer, M Rickenbach, R Lehmann, L Elzi, B Hirschel, ...
Clinical Infectious Diseases 45 (1), 111-119, 2007
|Predictive Value of Known and Novel Alleles of CYP2B6 for Efavirenz Plasma Concentrations in HIV‐infected Individuals|
M Rotger, H Tegude, S Colombo, M Cavassini, H Furrer, L Decosterd, ...
Clinical pharmacology & therapeutics 81 (4), 557-566, 2007
|CD4-guided scheduled treatment interruptions compared with continuous therapy for patients infected with HIV-1: results of the Staccato randomised trial|
J Ananworanich, A Gayet-Ageron, M Le Braz, W Prasithsirikul, ...
The Lancet 368 (9534), 459-465, 2006
|Evaluation of MRSA-Screen, a Simple Anti-PBP 2a Slide Latex Agglutination Kit, for Rapid Detection of Methicillin Resistance in Staphylococcus aureus|
M Cavassini, A Wenger, K Jaton, DS Blanc, J Bille
Journal of Clinical Microbiology 37 (5), 1591-1594, 1999
|Incidence of tuberculosis among HIV-infected patients receiving highly active antiretroviral therapy in Europe and North America|
Antiretroviral Therapy Cohort Collaboration
Clinical Infectious Diseases 41 (12), 1772-1782, 2005
|Randomized comparison of renal effects, efficacy, and safety with once-daily abacavir/lamivudine versus tenofovir/emtricitabine, administered with efavirenz, in antiretroviral …|
FA Post, GJ Moyle, HJ Stellbrink, P Domingo, D Podzamczer, M Fisher, ...
JAIDS Journal of Acquired Immune Deficiency Syndromes 55 (1), 49-57, 2010
|Smoking and life expectancy among HIV-infected individuals on antiretroviral therapy in Europe and North America|
M Helleberg, MT May, SM Ingle, F Dabis, P Reiss, G Fätkenheuer, ...
AIDS (london, England) 29 (2), 221, 2015
|Minority quasispecies of drug-resistant HIV-1 that lead to early therapy failure in treatment-naive and-adherent patients|
KJ Metzner, SG Giulieri, SA Knoepfel, P Rauch, P Burgisser, S Yerly, ...
Clinical infectious diseases 48 (2), 239-247, 2009